Korean Circ J.  2021 Sep;51(9):781-783. 10.4070/kcj.2021.0244.

Venous Thromboembolism in Heart Failure Patients: Building Evidence towards Better Care and the Need for Precision

• Lee SP

• KMID: 2519838
• DOI: http://doi.org/10.4070/kcj.2021.0244

Reference

1. Baek J, Lee H, Lee HH, Heo JE, Cho SM, Kim HC. Thirty-six year trends in mortality from diseases of circulatory system in Korea. Korean Circ J. 2021; 51:320–332. PMID: 33821581.

2. Lee HH, Cho SM, Lee H, et al. Korea Heart Disease Fact Sheet 2020: analysis of nationwide data. Korean Circ J. 2021; 51:495–503. PMID: 34085422.

3. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993–1004. PMID: 25176015.

4. Meijers WC, Maglione M, Bakker SJ, et al. Heart failure stimulates tumor growth by circulating factors. Circulation. 2018; 138:678–691. PMID: 29459363.

5. Xu T, Huang Y, Liu Z, et al. Heart failure is associated with increased risk of long-term venous thromboembolism. Korean Circ J. 2021; 51:766–780.

6. Fanola CL, Norby FL, Shah AM, et al. Incident heart failure and long-term risk for venous thromboembolism. J Am Coll Cardiol. 2020; 75:148–158. PMID: 31948643.

7. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018; 379:1332–1342. PMID: 30146935.

8. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377:1319–1330. PMID: 28844192.

9. Greenberg B, Neaton JD, Anker SD, et al. Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial. JAMA Cardiol. 2019; 4:515–523. PMID: 31017637.

10. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 369:2294–2303. PMID: 24251363.